Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ga-68 MAA Distribution in PAE Patients
NCT04243824Phase 1Withdrawn
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium 68 macroaggregated albumin in benign prostatic hyperplasia (BPH), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Ga-68 MAA radiotracer activity within adjacent organs at Day 1. Planned start May 2021; status: withdrawn.
02
Drugs
gallium 68 macroaggregated albumin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT04243824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04243824.